Protalix Biotherapeutics, Inc. (PLX)
2.37
+0.07
(+3.04%)
USD |
NYAM |
Jul 07, 16:00
2.36
-0.01
(-0.42%)
After-Hours: 20:00
Protalix Biotherapeutics Profit Margin (Quarterly) : 54.27% for March 31, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 54.27% |
| December 31, 2025 | -60.34% |
| September 30, 2025 | 13.19% |
| June 30, 2025 | 1.05% |
| March 31, 2025 | -35.79% |
| December 31, 2024 | 35.65% |
| September 30, 2024 | 18.02% |
| June 30, 2024 | -16.35% |
| March 31, 2024 | -122.6% |
| December 31, 2023 | -57.64% |
| September 30, 2023 | -17.90% |
| June 30, 2023 | 55.14% |
| March 31, 2023 | -32.66% |
| December 31, 2022 | -43.40% |
| September 30, 2022 | -25.15% |
| June 30, 2022 | -60.94% |
| March 31, 2022 | -14.21% |
| December 31, 2021 | -77.99% |
| September 30, 2021 | -34.83% |
| June 30, 2021 | -174.9% |
| March 31, 2021 | -48.37% |
| December 31, 2020 | 2.04% |
| September 30, 2020 | -41.12% |
| June 30, 2020 | -37.84% |
| March 31, 2020 | 7.70% |
| Date | Value |
|---|---|
| December 31, 2019 | 1.64% |
| September 30, 2019 | -24.99% |
| June 30, 2019 | -63.22% |
| March 31, 2019 | -69.59% |
| December 31, 2018 | -52.49% |
| September 30, 2018 | -43.15% |
| June 30, 2018 | -174.9% |
| March 31, 2018 | -206.5% |
| December 31, 2017 | -613.2% |
| September 30, 2017 | -152.0% |
| June 30, 2017 | 7.08% |
| March 31, 2017 | -2.05K% |
| December 31, 2016 | -126.1% |
| September 30, 2016 | -156.1% |
| June 30, 2016 | -606.9% |
| March 31, 2016 | -1.26K% |
| September 30, 2015 | -65.34% |
| June 30, 2015 | -109.9% |
| March 31, 2015 | -117.2% |
| December 31, 2014 | -611.9% |
| September 30, 2014 | -216.1% |
| June 30, 2014 | -227.8% |
| March 31, 2014 | -99.49% |
| December 31, 2013 | -970.1% |
| September 30, 2013 | -171.1% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Altimmune, Inc. | -- |
| Humacyte, Inc. | -3.56K% |
| Agenus, Inc. | -- |
| Amgen, Inc. | 21.02% |
| Anika Therapeutics, Inc. | -17.07% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 29.10% |
| Return on Assets | 18.28% |
| Return on Invested Capital | 25.64% |
| Gross Profit Margin (Quarterly) | 87.77% |
| Operating Margin (Quarterly) | 62.65% |
| Return on Net Operating Assets | 35.40% |